Company: SMNR
Filing Date: 2025-04-21
Form Type: S-4/A
Source: 0001193125-25-087342
Chunk: 743

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: S-4/A
Chunk 743
---
 into an Underwriter Letter Agreement, pursuant to which the Company’s Underwriters have agreed to receive 30%, or $ 866,250, of the aggregate $ 2,887,500deferred underwriting commission owed to them upon the closing of the Company’s initial business combination in the form of 86,625shares of shares of common stock of the combined company. Under the terms of the Underwriter Letter Agreement, the shares of common stock of the combined company will be issued at the Closing and the remaining aggregate $ 2,021,250of deferred underwriting compensation owed will remain payable at the Closing in cash under the original terms of the underwriting agreement. NOTE 7 – SHAREHOLDER’S DEFICIT Preference shares– The Company is authorized to issue 1,000,000preference shares with a par value of $ 0.0001per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2024 and December 31, 2023, there wereno preference shares issued and outstanding. Class A Ordinary Shares –The Company is authorized to issue 200,000,000Class A ordinary shares with a par value of $ 0.0001per share. As of December 31, 2024 and December 31, 2023, there were 510,000Class A ordinary shares issued and outstanding, excluding 751,837and 4,537,829Class A ordinary shares subject to possible redemption, respectively. F-28 Class B Ordinary Shares –The Company is authorized to issue 20,000,000Class B ordinary shares with a par value of $ 0.0001per share. As of December 31, 2024 and December 31, 2023, there were 2,062,500Class B ordinary shares issued and outstanding. On May 23, 2022, 93,750Class B ordinary shares were forfeited as the underwriters did not exercise the over-allotment option on the remaining 375,000Public Units. Prior to the Company’s initial Business Combination, only holders of Class B ordinary shares will have the right to vote on the appointment of directors and holders of a majority of the Company’s Class B ordinary shares may remove a member of the board of directors for any reason. In addition, in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval